Media, investors, advocacy organizations and others, please contact us here.

Events Nephrology

American Society of Nephrology (ASN) – Kidney Week

Information Type

Event Materials 16

Abstracts

Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)

View
Abstracts

Sparsentan (SPAR) vs Irbesartan (IRB) in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial

View
Abstracts

Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors in Patients With IgA Nephropathy in the PROTECT Open-Label Extension

View
Abstracts

Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety

View
Abstracts

Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: Preliminary Findings From the SPARTAN Trial

View
Abstracts

Sparsentan and Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in the PROTECT Open-Label Extension (OLE) Substudy and SPARTACUS: Trials in Progress

View
Posters

Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases

Posters

Sparsentan vs Irbesartan in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial

Posters

Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy

Contact Us

For more information, please click on the link below to be directed to our contact us form.

Adverse Event Reporting

To report suspected adverse reactions, contact Travere Therapeutics at 1-877-659-5518 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.